专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2015150360A1 BIOMARKERS FOR ASSESSING HIV 审中-公开
标题翻译：用于评估艾滋病毒的生物标志物
公开(公告)号：WO2015150360A1
公开(公告)日：2015-10-08
申请号：PCT/EP2015/056977
申请日：2015-03-31
申请人： IDCGS CLINICA DE DIAGNOSTICOS MEDICOS , CENTRO DE GENOMAS , BIOCRATES LIFE SCIENCES AG
发明人： DA SILVA, Ismael Dale Cotrim Guerreiro , LOTURCO, Edson Guimaraes , DIAZ, Ricoardo Soubie , KOAL, Therese
IPC分类号： G01N33/569 , G01N33/92 , G01N33/68
CPC分类号： G01N33/92 , C12Q1/70 , G01N33/56988 , G01N33/6812 , G01N33/6893 , G01N2333/47 , G01N2405/04 , G01N2405/08 , G01N2560/00 , G01N2800/52
摘要： The present invention relates to metabolic biomarker sets for assessing HIV. In preferred embodiments, the present invention relates to the use of biomarker sets for screening and/or diagnosing HIV infection, for prediction of immunologic response of a mammalian subject to antiretroviral therapy and/or prognosis of HIV disease progression, and for monitoring of HIV disease activity in a mammalian subject.In other embodiments, the invention relates to methods for screening and/or diagnosing HIV infection, for prediction of immunologic response of a mammalian subject to antiretroviral therapy and/or prognosis of HIV disease progression, and for monitoring of HIV disease activity in a mammalian subject, as well as to a kit adapted to carry out the methods. By employing the specific biomarkers and the method according to the present invention it becomes possible to more properly and reliably assess HIV. In particular, it becomes possible to screen for and diagnose HIV in a patient with high accuracy and predict early in advance the patient's therapeutic response to antiretroviral therapy.
摘要翻译：本发明涉及用于评估HIV的代谢生物标志物组。在优选的实施方案中，本发明涉及用于筛选和/或诊断HIV感染的生物标志物组的用途，用于预测哺乳动物受试者的抗逆转录病毒治疗和/或预防HIV疾病进展的免疫应答以及用于监测HIV疾病在其他实施方案中，本发明涉及用于筛选和/或诊断HIV感染的方法，用于预测哺乳动物受试者的抗逆转录病毒治疗和/或预防HIV疾病进展的免疫应答以及HIV的监测哺乳动物受试者的疾病活动，以及适于实施该方法的试剂盒。通过使用特定的生物标志物和根据本发明的方法，可以更正确和可靠地评价HIV。特别地，可以高精度地筛选和诊断患者中的HIV并预先提前预测患者对抗逆转录病毒疗法的治疗反应。

2. 发明申请

WO2020099683A1 METABOLITES FOR USE IN OVARIAN CANCER DETECTION AND DIAGNOSIS 审中-公开
公开(公告)号：WO2020099683A1
公开(公告)日：2020-05-22
申请号：PCT/EP2019/081689
申请日：2019-11-18
申请人： BIOCRATES LIFE SCIENCES AG
发明人： KOAL, Therese , BURWINKEL, Barbara , BAO-WEN, Yuan , MÜLLER, Udo , SCHAFFERER, Simon
IPC分类号： G01N33/50 , G01N33/574
摘要： The present invention relates to new metabolite panels for assessing ovarian cancer. Moreover, the present invention relates to a method for assessing ovarian cancer from a subject to be examined, and to a kit for carrying out the method.

3. 发明申请

WO2018049268A1 BIOMARKERS FOR THE DIAGNOSIS AND CHARACTERIZATION OF ALZHEIMER'S DISEASE 审中-公开
标题翻译：生物标志物用于阿尔茨海默病的诊断和表征
公开(公告)号：WO2018049268A1
公开(公告)日：2018-03-15
申请号：PCT/US2017/050831
申请日：2017-09-08
申请人： DUKE UNIVERSITY , UNIVERSITY OF PENNSYLVANIA , HOUSTON METHODIST HOSPITAL , HELMHOLTZ ZENTRUM MUNCHEN , GERMAN CENTER FOR DIABETES RESEARCH (DZD) , ROSA & CO LLC , SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE , INDIANA UNIVERSITY SCHOOL OF MEDICINE , BIOCRATES LIFE SCIENCES AG , TOLEDO, Jon, B. , ARNOLD, Matthias , KASTEMULLER, Gabi , BAILLIE, Rebecca, A. , HAN, Xianlin , THOMPSON, Will , ST. JOHN-WILLIAMS, Lisa , KOAL, Therese , NHO, Kwangsik , MOSELEY, M., Arthur , SAYKIN, Andrew, J. , DORAISWAMY, Pudugramam, Murali
发明人： TOLEDO, Jon, B. , ARNOLD, Matthias , KASTEMULLER, Gabi , BAILLIE, Rebecca, A. , HAN, Xianlin , THOMPSON, Will , ST. JOHN-WILLIAMS, Lisa , KOAL, Therese , MOSELEY, M., Arthur , SAYKIN, Andrew, J. , DORAISWAMY, Pudugramam, Murali
IPC分类号： G01N33/50 , A61K31/661 , G01N33/92
摘要： Embodiments of the present disclosure relate generally to the analysis and identification of global metabolic changes in Alzheimer's disease (AD). More particularly, the present disclosure provides materials and methods relating to the use of metabolornics as a biochemical approach to identify peripheral metabolic changes in AD patients and correlate them to cerebrospinal fluid pathology markers, imaging features, and cognitive performance. Defining metabolic changes during AD disease trajectory and their relationship to clinical phenotypes provides a powerful roadmap for drug and biomarker discovery.
摘要翻译：本公开的实施方案一般涉及阿尔茨海默病（AD）中全局代谢变化的分析和鉴定。更具体地说，本公开提供了与使用代谢物作为生化方法相关的材料和方法，以鉴定AD患者中的外周代谢变化并将它们与脑脊液流体病理学标记，成像特征和认知表现相关联。定义AD疾病过程中的代谢变化及其与临床表型的关系为药物和生物标志物的发现提供了强有力的路线图。

4. 发明申请

WO2011012553A1 METHOD FOR PREDICTING THE LIKELIHOOD OF AN ONSET OF AN INFLAMMATION ASSOCIATED ORGAN FAILURE 审中-公开
标题翻译：预测感染相关器官失败发生率的方法
公开(公告)号：WO2011012553A1
公开(公告)日：2011-02-03
申请号：PCT/EP2010/060745
申请日：2010-07-23
申请人： BIOCRATES LIFE SCIENCES AG , DEIGNER, Hans-Peter , KOHL, Matthias , ENOT, David , KOAL, Therese , KELLER, Matthias
发明人： DEIGNER, Hans-Peter , KOHL, Matthias , ENOT, David , KOAL, Therese , KELLER, Matthias
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2800/26 , G06F19/12 , G06F19/24 , Y10T436/173845
摘要： The present invention relates to a reliable and statistically significant method for predicting the likelihood of an onset of an inflammation associated organ failure from a biological sample of a mammalian subject in vitro, by means of a subject's quantitative metabolomics profile comprising a plurality of endogenous metabolites, and comparing it with a quantitative reference metabolomics profile of a plurality of endogenous organ failure predictive target metabolites in order to predict whether the subject is likely or unlikely to develop an organ failure. Furthermore, the invention relates to the usefulness of endogenous organ failure predictive target metabolites in such a method.
摘要翻译：本发明涉及用于通过受试者的定量代谢组学谱来预测来自哺乳动物受试者的体外生物样品的炎症相关器官功能衰竭发作的可能性的可靠和统计学显着的方法，该定量代谢组学特征包括多种内源性代谢物，并将其与多种内源性器官衰竭预测目标代谢物的定量参考代谢组学谱进行比较，以便预测受试者是否可能或不可能发生器官功能衰竭。此外，本发明涉及在这种方法中内源性器官衰竭预测目标代谢物的有用性。

5. 发明申请

WO2011000753A1 METHOD FOR NORMALIZATION IN METABOLOMICS ANALYSIS METHODS WITH ENDOGENOUS REFERENCE METABOLITES 审中-公开
标题翻译：具有内源性参考代谢物的代谢分析方法的正规化方法
公开(公告)号：WO2011000753A1
公开(公告)日：2011-01-06
申请号：PCT/EP2010/058911
申请日：2010-06-23
申请人： BIOCRATES Life Sciences AG , DEIGNER, Hans-Peter , KOHL, Matthias , KELLER, Matthias , KOAL, Therese
发明人： DEIGNER, Hans-Peter , KOHL, Matthias , KELLER, Matthias , KOAL, Therese
IPC分类号： G06F19/00
CPC分类号： G06F19/24 , G01N2800/60 , Y10T436/163333 , Y10T436/201666
摘要： The present invention relates to the use of endogenous reference metabolites and a method for normalization of intensity data corresponding to amounts and/or concentrations of selected target metabolites in a biological sample of a mammalian subject, wherein said intensity data are obtained by a metabolomics analysis method with one or a plurality of endogenous reference metabolites, comprising carrying out at least one in vitro metabolomics analysis method of said selected target metabolites in said biological sample, simultaneously carrying out in the same sample a quantitative analysis of one or a plurality of endogenous reference metabolites or derivatives thereof, wherein said endogenous reference metabolites are such compounds in the biological sample which are present in the subject at an essentially constant level; and wherein said endogenous reference metabolites or derivatives thereof have a molecular mass less than 1500 Da.
摘要翻译：本发明涉及内源性参考代谢物的使用以及对应于哺乳动物受试者的生物样品中所选靶标代谢物的量和/或浓度的强度数据的归一化方法，其中所述强度数据通过代谢组学分析法与一种或多种内源性参考代谢物，包括在所述生物样品中进行所述选择的目标代谢物的至少一种体外代谢组学分析方法，同时在相同样品中进行一种或多种内源性参考代谢物的定量分析或其衍生物，其中所述内源性参考代谢物是生物样品中以基本恒定水平存在于受试者中的这样的化合物; 并且其中所述内源性参考代谢物或其衍生物具有小于1500Da的分子量。

6. 发明申请

WO2011157655A1 USE OF BILE ACIDS FOR PREDICTION OF AN ONSET OF SEPSIS 审中-公开
标题翻译：使用双酸来预测食欲的上升
公开(公告)号：WO2011157655A1
公开(公告)日：2011-12-22
申请号：PCT/EP2011/059699
申请日：2011-06-10
申请人： BIOCRATES LIFE SCIENCES AG , DEIGNER, Hans-Peter , KOHL, Matthias , KOAL, Therese , IGWE, Ignatius Emeka , DALLMANN, Guido , BAUER, Michael , ENOT, David
发明人： DEIGNER, Hans-Peter , KOHL, Matthias , KOAL, Therese , IGWE, Ignatius Emeka , DALLMANN, Guido , BAUER, Michael , ENOT, David
IPC分类号： G01N33/50 , G01N33/92
CPC分类号： G01N33/6893 , G01N30/7233 , G01N33/6848 , G01N33/92 , G01N2030/8813 , G01N2800/24 , G01N2800/26 , G01N2800/50
摘要： The present invention relates to a method for in vitro predicting the likelihood of an onset of sepsis, by quantitatively detecting in at least one biological sample of a patient a plurality of endogenous sepsis predictive target compounds having a molecular weight of less than 1500 Dalton comprising the steps of: selecting said compounds from the group of bile acids, measuring concentration, level or amount of each individual endogenous sepsis predictive target compound of said plurality of compounds in said sample, establishing a quantitative pattern; and using and storing the obtained set of values in a database. Calibrating said values by comparing clinically confirmed sepsis-positive and/or clinically confirmed sepsis-negative reference parameters, and comparing said measured values in the sample with the calibrated values, in order to assess whether the patient is likely to develop a sepsis or not.
摘要翻译：本发明涉及通过在患者的至少一个生物样品中定量检测多个分子量小于1500道尔顿的内源性败血症预测靶化合物来体外预测败血症发作的可能性的方法，所述内源性败血症预测靶化合物包含步骤：从所述胆汁酸组中选择所述化合物，测量所述样品中所述多种化合物的每种单独内源性败血症预测目标化合物的浓度，水平或量，建立定量模式; 并将获得的值集合使用并存储在数据库中。通过比较临床证实的败血症阳性和/或临床证实的败血症阴性参考参数，并将样本中的所述测量值与校准值进行比较来校准所述值，以评估患者是否可能发展为败血症。

7. 发明申请

WO2016038157A1 BIOMARKERS FOR ASSESSING BREAST CANCER 审中-公开
标题翻译：用于评估乳腺癌的生物标志物
公开(公告)号：WO2016038157A1
公开(公告)日：2016-03-17
申请号：PCT/EP2015/070752
申请日：2015-09-10
申请人： IDCGS CLÍNICA DE DIAGNÓSTICOS MÉDICOS LTDA , BIOCRATES LIFE SCIENCES AG , FUNDAÇÃO PIO XII HOSPITAL DE CÂNCER DE BARRETOS CNPJ/MF
发明人： LOPES CARVALHO, Andre , DA COSTA VIEIRA, René Aloisio , GUERREIRO DA SILVA, Ismael Dale Cotrim , GUIMARAES LO TURCO, Edson , KOAL, Therese
IPC分类号： G01N33/574
CPC分类号： G01N33/57415 , A61B5/00 , A61B5/41 , G01N33/57484 , G01N2333/71 , G01N2333/90 , G01N2570/00 , G01N2800/50 , G01N2800/52
摘要： The present invention relates to a metabolic biomarker set for use in assessing breast cancer in a mammalian subject. In particular, the invention relates to a metabolic biomarker set for screening and/or diagnosing breast cancer, the metabolic biomarker set comprising at least (a) one amino acid selected from glutamine, glutamate and serine, and one lipid, or (b) glutamine and glutamate. Further, the invention relates to a metabolic biomarker set for prediction of therapeutic response to breast cancer neoadjuvant chemotherapy. Further, the invention relates to a metabolic biomarker set for assessing biochemical reflection of breast cancer tumor activity. Further, the invention relates to a metabolic biomarker set for subclassification between intrinsic breast cancer tumor subtypes. Moreover, the present invention relates to a method for assessing breast cancer, which comprises obtaining a biological sample, preferably blood, from a mammalian subject and measuring in the biological sample the amount and/or ratios of metabolites. By employing the specific biomarkers and the method according to the present invention it becomes possible to more properly and reliably assess breast cancer.
摘要翻译：本发明涉及用于在哺乳动物受试者中评估乳腺癌的代谢生物标志物组。特别地，本发明涉及用于筛选和/或诊断乳腺癌的代谢生物标志物组，所述代谢生物标志物组包含至少（a）一种选自谷氨酰胺，谷氨酸和丝氨酸的氨基酸和一种脂质，或（b）谷氨酰胺和谷氨酸。此外，本发明涉及用于预测乳腺癌新辅助化疗的治疗反应的代谢生物标志物组。此外，本发明涉及用于评估乳腺癌肿瘤活性的生物化学反应的代谢生物标志物组。此外，本发明涉及用于内在乳腺癌肿瘤亚型之间的分类的代谢生物标志物。此外，本发明涉及一种用于评估乳腺癌的方法，其包括从哺乳动物受试者获得生物样品，优选血液，并在生物样品中测量代谢物的量和/或比例。通过使用具体的生物标志物和根据本发明的方法，可以更正确和可靠地评估乳腺癌。

8. 发明申请

WO2011080184A1 USE OF ENDOGENOUS METABOLITES FOR EARLY DIAGNOSING SEPSIS 审中-公开
标题翻译：使用内源性代谢物进行早期诊断SEPSIS
公开(公告)号：WO2011080184A1
公开(公告)日：2011-07-07
申请号：PCT/EP2010/070544
申请日：2010-12-22
申请人： BIOCRATES LIFE SCIENCES AG , DEIGNER, Hans-Peter , ENOT, David , KOHL, Matthias , IGWE, Emeka , KOAL, Therese , BAUER, Michael , DALLMANN, Guido
发明人： DEIGNER, Hans-Peter , ENOT, David , KOHL, Matthias , IGWE, Emeka , KOAL, Therese , BAUER, Michael , DALLMANN, Guido
IPC分类号： G01N33/92
CPC分类号： G01N33/92 , G01N2800/26
摘要： The present invention relates to a use of a plurality of endogenous target metabolites for predicting a likelihood of an onset of a sepsis from a biological sample of a mammalian subject in vitro, wherein said endogenous target metabolites have a molecular mass less than 1500 Da and are selected from the group of oxysterols.
摘要翻译：本发明涉及多种内源性目标代谢物用于从体外预测来自哺乳动物受试者的生物样品的脓毒症发作的可能性的用途，其中所述内源靶标代谢物具有小于1500Da的分子量，并且分别为选自氧固醇组。

9. 发明申请

WO2010128054A1 METHOD OF DIAGNOSING ASPHYXIA 审中-公开
标题翻译：诊断ASPHYXIA的方法
公开(公告)号：WO2010128054A1
公开(公告)日：2010-11-11
申请号：PCT/EP2010/056048
申请日：2010-05-04
申请人： BIOCRATES LIFE SCIENCES AG , KELLER, Matthias , DEIGNER, Hans-Peter , ENOT, David , KOHL, Matthias , SOLBERG, Ronnaug , SAUGSTAD, Ola Didrik , KOAL, Therese
发明人： KELLER, Matthias , DEIGNER, Hans-Peter , ENOT, David , KOHL, Matthias , SOLBERG, Ronnaug , SAUGSTAD, Ola Didrik , KOAL, Therese
IPC分类号： G01N33/68 , G06F19/00
CPC分类号： G01N33/6893 , G01N2800/12 , G06F19/24 , Y02A90/26
摘要： The present invention relates to a method for in vitro diagnosing asphyxia and disorders related thereto, to a method of in vitro estimating duration of hypoxia in a patient subjected to asphyxia, and to a method for in vitro monitoring of normoxic, hypoxic and hyperoxic conditions and/or normobaric and hyperbaric oxygen therapy, characterized by quantitatively detecting in a biological sample of a patient a plurality of asphyxia specific endogenous compounds which are selected from the group consisting of biogenic amines; carnitine-derived compounds; amino acids; bile acids; carboxylic acids; eicosanoids; lipids; precursors of cholesterol, cholesterol metabolites; prostanoids; and sugars.
摘要翻译：本发明涉及一种用于体外诊断窒息和相关疾病的方法，体外估计患有窒息的患者的缺氧持续时间的方法，以及用于体外监测正常氧，缺氧和高氧条件的方法，以及 /或常压和高压氧疗法，其特征在于在患者的生物样品中定量检测多种选自生物胺的窒息特异性内源性化合物; 肉碱衍生化合物; 氨基酸; 胆汁酸羧酸; 花生酸类; 脂质; 胆固醇前体，胆固醇代谢物; 前列腺素; 和糖。

10. 发明申请

WO2010115833A1 METHOD FOR IN VITRO DIAGNOSING A COMPLEX DISEASE 审中-公开
标题翻译：用于诊断复杂疾病的方法
公开(公告)号：WO2010115833A1
公开(公告)日：2010-10-14
申请号：PCT/EP2010/054384
申请日：2010-03-31
申请人： BIOCRATES LIFE SCIENCES AG , DEIGNER, Hans-Peter , KOHL, Matthias , KELLER, Matthias , KOAL, Therese , WEINBERGER, Klaus
发明人： DEIGNER, Hans-Peter , KOHL, Matthias , KELLER, Matthias , KOAL, Therese , WEINBERGER, Klaus
IPC分类号： G06F19/00
CPC分类号： G06F19/28 , C12Q1/6886 , C12Q2600/158 , C12Q2600/178 , G06F19/18 , G06F19/20 , G06F19/24
摘要： The present invention relates to a method and kit for in vitro diagnosing a complex disease such as cancer, in particular, acute myeloid leukemia (AML), colon cancer, kidney cancer, prostate cancer; transient ischemic attack (TIA), ischemia, in particular stroke, hypoxia, hypoxic-ischemic encephalopathy, perinatal brain damage, hypoxic- ischemic encephalopathy of neotatals asphyxia; demyelinating disease, in particular, white-matter disease, periventricular leukoencephalopathy, multiple sclerosis, Alzheimer and Parkinson's disease; in a biological sample. For the diagnosis, use is made of measuring at least two different species of biomolecules and classifying the results by means of suitable classifier algorithms and other statistical procedures. With the present invention, a significant improvement of the reliability of, e.g. expression profiles alone, are achieved. In other words, in a defined collective, an up to 100% accurate positive diagnosis could be achieved, which renders the method of the present invention superior over the prior art.
摘要翻译：本发明涉及用于体外诊断复杂疾病如癌症，特别是急性骨髓性白血病（AML），结肠癌，肾癌，前列腺癌的方法和试剂盒; 短暂性脑缺血发作（TIA），缺血，特别是中风，缺氧，缺氧缺血性脑病，围产期脑损伤，缺氧缺血性脑病的新生儿窒息; 脱髓鞘疾病，特别是白质病，脑室周围脑白质病，多发性硬化，阿尔茨海默病和帕金森病; 在生物样品中。对于诊断，使用测量至少两种不同种类的生物分子，并通过适当的分类器算法和其他统计程序对结果进行分类。利用本发明，可靠性的显着改善，例如，单独表达谱。换句话说，在定义的集体中，可以实现高达100％的准确的阳性诊断，这使得本发明的方法优于现有技术。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式